Long-term efficacy and downstream mechanism of anti-annexinA2 monoclonal antibody (anti-ANX A2 mAb) in a pre-clinical model of aggressive human breast cancer.

Authors

Mahesh C Sharma
George P Tuszynski
Marc R. Blackman, George Washington UniversityFollow
Meena Sharma

Document Type

Journal Article

Publication Date

4-1-2016

Journal

Cancer Letters

Volume

373

Issue

1

Inclusive Pages

27-35

DOI

10.1016/j.canlet.2016.01.013

Keywords

Annexin A2--antagonists & inhibitors; Antibodies, Monoclonal--pharmacology; Antineoplastic Agents--pharmacology; Breast Neoplasms--drug therapy

APA Citation

Sharma, M.C., Tuszynski, G.P., Blackman, M.R., Sharma, M. (2016). Long-term efficacy and downstream mechanism of anti-annexinA2 monoclonal antibody (anti-ANX A2 mAb) in a pre-clinical model of aggressive human breast cancer. Cancer Letters, 373(1), 27-35. doi: 10.1016/j.canlet.2016.01.013.

Peer Reviewed

1